CP 6232
Latest Information Update: 18 May 2011
At a glance
- Originator Meiji Seika Kaisha
- Developer Meiji Seika Pharma
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections